Bank of New York Mellon Corp Grows Position in Celcuity Inc. (NASDAQ:CELC)

Bank of New York Mellon Corp raised its stake in shares of Celcuity Inc. (NASDAQ:CELC) by 42.7% during the 2nd quarter, Holdings Channel.com reports. The fund owned 66,256 shares of the company’s stock after acquiring an additional 19,811 shares during the period. Bank of New York Mellon Corp’s holdings in Celcuity were worth $1,085,000 as of its most recent SEC filing.

A number of other hedge funds have also recently bought and sold shares of the company. BNP Paribas Financial Markets lifted its position in shares of Celcuity by 78.5% during the 1st quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock worth $193,000 after buying an additional 3,930 shares in the last quarter. Pale Fire Capital SE lifted its holdings in Celcuity by 38.4% during the fourth quarter. Pale Fire Capital SE now owns 14,409 shares of the company’s stock worth $210,000 after acquiring an additional 4,000 shares during the period. Wealth Enhancement Advisory Services LLC boosted its position in Celcuity by 7.8% in the second quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock worth $361,000 after purchasing an additional 1,600 shares during the last quarter. Hennion & Walsh Asset Management Inc. bought a new position in Celcuity in the 2nd quarter valued at $888,000. Finally, Healthcare of Ontario Pension Plan Trust Fund purchased a new stake in shares of Celcuity during the 1st quarter valued at $3,545,000. 63.33% of the stock is owned by hedge funds and other institutional investors.

Celcuity Trading Down 2.2 %

NASDAQ:CELC opened at $14.85 on Friday. Celcuity Inc. has a 1 year low of $8.39 and a 1 year high of $22.19. The stock’s fifty day moving average price is $16.66 and its two-hundred day moving average price is $16.90. The company has a debt-to-equity ratio of 0.54, a current ratio of 14.95 and a quick ratio of 14.95. The company has a market cap of $521.25 million, a P/E ratio of -5.34 and a beta of 0.76.

Celcuity (NASDAQ:CELC) last issued its earnings results on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. During the same period in the prior year, the company posted ($0.66) earnings per share. As a group, analysts expect that Celcuity Inc. will post -2.54 EPS for the current year.

Analyst Ratings Changes

A number of equities analysts recently weighed in on CELC shares. Lifesci Capital started coverage on shares of Celcuity in a report on Monday, August 26th. They issued an “outperform” rating and a $27.00 price target on the stock. Leerink Partners began coverage on shares of Celcuity in a research report on Monday, July 22nd. They set an “outperform” rating and a $29.00 target price for the company. Needham & Company LLC restated a “buy” rating and set a $23.00 price target on shares of Celcuity in a research note on Thursday, August 15th. HC Wainwright reiterated a “buy” rating and issued a $27.00 price objective on shares of Celcuity in a research note on Thursday, August 15th. Finally, Leerink Partnrs raised Celcuity to a “strong-buy” rating in a report on Monday, July 22nd. Six analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Celcuity presently has an average rating of “Buy” and an average target price of $28.67.

Celcuity Company Profile

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.